Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Madrigal PharmaceuticalsMDGL +2.57%31 3-Year EBITDA Growth Rate is 11.40% as of Jun. 2026. GuruFocus rates MDGL with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,136 Biotechnology companies, Madrigal Pharmaceuticals ranks worse than 54.93% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -1.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -13.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Madrigal Pharmaceuticals was 55.50% per year. The lowest was -158.00% per year. And the median was -2.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Madrigal Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
MDGL vs AXSM, ARWR, BMRN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Madrigal Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.40% mean?
Madrigal Pharmaceuticals (MDGL) has a 3-Year EBITDA Growth Rate of 11.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Madrigal Pharmaceuticals and its competitors. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #624 out of 1136 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Madrigal Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Madrigal Pharmaceuticals' current 3-Year EBITDA Growth Rate is 11.40%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Madrigal Pharmaceuticals' value of 11.40% is 23.2% below this industry median. Based on the distribution chart, Madrigal Pharmaceuticals ranks #624 out of 1136 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Madrigal Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' 3-Year EBITDA Growth Rate compare to AXSM and ARWR?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #624 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Madrigal Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Madrigal Pharmaceuticals' value of 11.40% is 23.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Madrigal Pharmaceuticals's current 3-Year EBITDA Growth Rate of 11.40% is 23.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Madrigal Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madrigal Pharmaceuticals's current 3-Year EBITDA Growth Rate is 11.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MDGL) has a current 3-Year EBITDA Growth Rate of 11.40%. The current 3-Year EBITDA Growth Rate is 11.40% and 23.2% below the Biotechnology industry median of 14.85. Madrigal Pharmaceuticals' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MDGL), the current 3-Year EBITDA Growth Rate is 11.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
31GF Score
Get the complete analysis for MDGL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDGL has been successfully added to your 
